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Abstract
Introduction Dendritic cells (DCs) are antigen-presenting cells
that are currently employed in cancer clinical trials. However, it
is not clear whether their ability to induce tumour-specific
immune responses when they are isolated from cancer patients
is reduced relative to their ability in vivo. We determined the
phenotype and functional activity of DCs from cancer patients
and investigated the effect of putrescine, a polyamine molecule
that is released in large amounts by cancer cells and has been
implicated in metastatic invasion, on DCs.
Methods The IL-4/GM-CSF (granulocyte–macrophage colony-
stimulating factor) procedure for culturing blood monocyte-
derived DCs was applied to cells from healthy donors and
patients (17 with breast, 7 with colorectal and 10 with renal cell
carcinoma). The same peroxide-treated tumour cells (M74 cell
line) were used for DC pulsing. We investigated the effects of
stimulation of autologous lymphocytes by DCs pulsed with
treated tumour cells (DC-Tu), and cytolytic activity of T cells was
determined in the same target cells.
Results Certain differences were observed between donors
and breast cancer patients. The yield of DCs was dramatically
weaker, and expression of MHC class II was lower and the
percentage of HLA-DR-Lin- cells higher in patients. Whatever
combination of maturating agents was used, expression of
markers of mature DCs was significantly lower in patients. Also,
DCs from patients exhibited reduced ability to stimulate
cytotoxic T lymphocytes. After DC-Tu stimulation, specific
cytolytic activity was enhanced by up to 40% when DCs were
from donors but only up to 10% when they were from patients.
IFN-γ production was repeatedly found to be enhanced in
donors but not in patients. By adding putrescine to DCs from
donors, it was possible to enhance the HLA-DR-Lin-  cell
percentage and to reduce the final cytolytic activity of
lymphocytes after DC-Tu stimulation, mimicking defective DC
function. These putrescine-induced deficiencies were reversed
by treating DCs with all-trans retinoic acid.
Conclusion These data are consistent with blockade of antigen-
presenting cells at an early stage of differentiation in patients
with breast cancer. Putrescine released in the
microenvironmement of DCs could be involved in this blockade.
Use of all-trans retinoic acid treatment to reverse this blockade
and favour ex vivo expansion of antigen-specific T lymphocytes
is of real interest.
ATRA = all-trans retinoic acid; CTL = cytolytic T lymphocyte; DC = dendritic cell; DC-Tu = DCs pulsed with treated tumour cells; GM-CSF = gran-
ulocyte–macrophage colony-stimulating factor; IFN = interferon; IL = interleukin; MHC = major histocompatibility complex; MNC = mononuclear cell; 
NK = natural killer; TA = tumour antigen.Breast Cancer Research    Vol 7 No 3    Gervais et al.
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Introduction
The role played by T cell mediated immunity in the control of
tumour growth has been established over recent years. As a
result, most immunization strategies adopted in clinical trials of
cancer treatments have aimed at enhancing tumour antigen
(TA)-specific cellular immunity. The induction and expansion of
TA-specific T cells requires optimal antigen presentation and
T-cell co-stimulation. Dendritic cells (DCs) are specialized
antigen-presenting cells with a remarkable ability to stimulate
naïve T lymphocytes and generate memory T lymphocytes [1].
However, objective response rates to vaccine or DC trials in
cancer remain low [2]. Differentiation and maturation of DCs
are important to their protective activity against tumour devel-
opment [3]. Exposure to necrotic tumor cells can induce mat-
uration of immunostimulatory DCs [4] but the involved
mechanisms are still unresolved [5].
Cytotoxic T lymphocytes (CTLs) directed against tumour cells
can be amplified in vitro with the use of DCs pulsed with
treated tumour cells (DC-Tu) [6]. When assays were done
with cells from healthy donors, DC-Tu stimulation repeatedly
increased the final cytolytic activity of T cells more than two-
fold. However, we observed that a similar procedure applied
to cells from cancer patients enhanced the final cytotoxic activ-
ity against autologous tumour only in half of the assays [6]. We
noticed in these experiments that the final yield and phenotype
of blood-derived myeloid immature DCs was heterogeneous in
cancer patients [6]. These findings could be related to a rela-
tionship between immune suppression instilled during tumour
development, as previously described by Kusmartsev and
Gabrilovich [7], and increased production of immature myeloid
cells in patients with advanced cancers [8].
Our aim in the present study was to detail the differences in
characteristics of DCs between patients with cancer and
healthy donors. We investigated blood cells from patients with
breast, colorectal, or renal carcinoma and compared them,
using the same assays, with cells from healthy donors. DCs
were obtained from peripheral blood [9] and matured using
various cocktails combining proinflammatory cytokines and
danger or co-stimulating signals that are known for their ability
to induce a T-helper-1 phenotype [3,10]. Tumour cells were
from the M74 melanoma cell line in all of the assays. Treatment
of tumour cells was done for induction of late apoptosis
(postapoptotic necrotic tumour cells) [11]. Necrotic cells were
chosen for DC pulsing, in accordance with previous reports
[5,12,13] and preliminary experiments by our group that dem-
onstrated that processing and cross-presentation of TA led to
specific CTL responses in DCs pulsed under these conditions
(Gervais A, unpublished data).
The ultimate mechanisms by which DC deficiency is estab-
lished are not understood. The tumour microenvironment is
rich in growth factors and molecules that are able to modulate
the immune response of the host. Polyamines, which are con-
ducive to proliferation and metastatic invasion, are synthesized
in large amounts by tumour cells [14]. A therapeutic strategy
combining inhibition of all cellular and exogenous sources of
polyamines has been evaluated in several murine tumour mod-
els, with positive findings [15]. However, the role played by
polyamines in immune processes is poorly understood
[16,17]. Nevertheless, our group showed that polyamine dep-
rivation can prevent the development of in vivo tumour-
induced immunosuppression [18]. In the present study, the
hypothesis that putrescine is involved in immunodeficiency
was tested by investigating the effects of putrescine on func-
tional activity of DCs from donors. This treatment was able to
mimic the abnormalities observed in DCs from patients with
breast cancer.
Materials and methods
Patients
Thirty-four patients with histologically confirmed cancer were
enroled in the study. Seventeen (age 47–76 years) had breast
cancer: 13 had infiltrating ductal carcinoma (grade I-III; Elston
Ellis grading); one was invasive lobular carcinoma (grade III);
one was mixed ductal-lobular carcinoma (grade I); and two
were in situ ductal carcinomas (low and high grade). Seven
(age 33–86 years) had colorectal cancer (stage 2–4 adeno-
carcinoma) and 10 (age 42–78 years) had renal cell carci-
noma (Fuhrman grade III clear cell carcinoma). Patients were
newly diagnosed and peripheral blood samples were col-
lected at the time of initial surgery, with no prior therapy. The
study was approved by the regional ethics committee (Comité
Consultatif de Protection des Personnes dans la Recherche
Biomédicale de Rennes, Rennes, France). Eleven healthy vol-
unteers (HLA-A2) served as control individuals (Etablissement
Français du Sang, Rennes, France).
Isolation of cells from peripheral blood
Cells were centrifuged by applying a density gradient (UNI-
SEP®; Novamed, Jerusalem, Israel). Mononuclear cells
(MNCs) were frozen in human serum albumin and 10% dime-
thyl sulphoxide until use for DC and lymphocyte preparation.
Tumour cell treatment
The HLA-A2 MelanA-Mart1 expressing M74 melanoma cell
line was used for both antigen DC pulsing and as a target for
evaluation of specific cytotoxic activity. This cell line and the
K562 natural killer (NK) cell-sensitive erythroleukaemia cell
line were maintained in RPMI 1640 medium (Eurobio, Les Ulis,
France) containing 10% foetal calf serum (Gibco Invitrogen
Life Technologies, Cergy Pontoise, France), 1 mmol/l L-
glutamine, 50 µg/ml streptomycin and 50 IU/ml penicillin (ICN
Biomedicals, Aurora, OH, USA).
M74 cells were used for TA DC pulsing following necrosis-
inducing treatment. The method was adapted from that pre-
sented by Lennon and coworkers [11]. Briefly, cells were
treated with hydrogen peroxide 10 µmol/l (Sigma-Aldrich,Available online http://breast-cancer-research.com/content/7/3/R326
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Saint Quentin-Fallavier, France) for 3 consecutive days.
Supernatant cells were collected each day, pooled and kept at
4°C. Collected cells (M74 per) were used for DC pulsing (DC-
Tuper).
Treated tumour cells were examined for degree of apoptosis
and secondary necrosis using a standard fluorescence-acti-
vated cell sorting assay (Annexin V-FITC detection kit; Immu-
notech, Marseille, France), which detects binding of annexin V
(A) and propidium iodide inclusion/exclusion. With 10 µmol/l
peroxide, 16% of the collected cells were apoptotic (annexin
V positive/propidium iodide negative) and 50% were in a state
of postapoptotic necrosis (annexin V positive/propidium
iodide positive).
Culture of dendritic cells
DCs were prepared from MNCs (from patients or healthy
donors) in accordance with the method described by Sallusto
and Lanzavecchia [9]. Briefly, 10 × 106 MNCs were seeded in
5 ml serum-free X-Vivo 10 medium (Biowhittaker, Walkersville,
MD, USA) in a 25 cm2  culture flask (Cellstar®; Greiner
Labortechnik, Frickenhausen, Germany). Nonadherent cells
were collected after 2 hours for lymphocyte culture. The
remaining adherent cells were cultured in DC medium: serum
free X-Vivo 10 medium supplemented with 10% AB serum
(EFS de Rennes, Rennes, France), 10 µg/ml steptomycin and
100 IU/ml penicillin. Granulocyte–macrophage colony-stimu-
lating factor (GM-CSF) 1000 IU/ml (Leucomax 400™;
Novartis/Shering Plough, Huningue, France, Switzerland) and
400 IU/ml IL-4 (Promokine; Promocell, Heidelberg, Germany)
were added on days 0, 2 and 5 of culture. After 7 days nonad-
herent cells (immature DCs) were collected and added to per-
oxide-treated M74 cells (ratio 1:10) for antigen processing.
After 18 hours of contact, supernatant cells (DC-Tuper) were
added to autologous lymphocytes (DC:lymphocyte ratio
1:100) for lymphocyte stimulation. DCs were phenotypically
characterized before lymphocyte stimulation (day 8).
For maturation assays, immature DCs were seeded in DC
medium (density 106 cells/ml) in 24-well plates (Falcon®; Bec-
ton Dickinson, Franklin Lakes, NJ, USA) and maturating agents
were immediately added. Three different maturation cocktails
were evaluated. The first (cocktail A) was a combination of
tumour necrosis factor-α (25 ng/ml; Pharmingen, San Diego,
CA, USA), lipopolysaccharide (10 µg/ml; Sigma-Aldrich) and
CD40L (0.4 µg/ml; Alexis Biochemicals, QBiogene, Illkirch,
France). The second (cocktail B) was a combination of IL-1β
(10 ng/ml), IL-6 (1000 U/ml), tumour necrosis factor-α (10 ng/
ml; R&D systems, Lille, France) and prostaglandin E2 (1 µg/ml;
Sigma-Aldrich). The third (cocktail C) was a combination of
bacterial extracts (1 µg/ml; Ribomunyl®; Pierre Fabre Médica-
ment, Boulogne, France) and IFN-γ (1000 U/ml; Imukin®, Boe-
hringer Ingelheim, Reims, France). After 18 hours of contact,
supernatant cells (matured DCs) were collected and pheno-
typically characterized (day 8).
Phagocytic activity of dendritic cells
Phagocytic activity was evaluated using FITC-labelled
opsonized bacteria (Escherichia coli; Phago Test®; OrpeGen
Pharma, Heidelberg, Germany). Immature DCs from patients
or donors and opsonized bacteria were co-cultured for 2 hours
at 37°C and their internalization was evaluated by flow cytom-
etry, in accordance with the manufacturer's recommendations.
Controls were run at +4°C.
IL-10 and IL-12 production
Measurements of IL-10 and IL-12 were done in supernatants
of immature DCs and mature DCs after 72 hours in culture at
37°C. Assays were done using enzyme-linked immunosorbent
assay methods according to the manufacturer's instructions
(Ready-set-Go®; eBioscience, San Diego, CA, USA) and
were performed in duplicate.
Dendritic cell treatments
Immature DCs were treated for 18 hours with 10 mmol/l
putrescine (1,4-diaminobutane dihydrochloride; Sigma-
Aldrich) before phenotype or functional activity were meas-
ured. Because it was reported that all-trans  retinoic acid
(ATRA) can reduce the number of immature myeloid cells and
favour their differentiation into DCs [8], putrescine-treated
immature DCs were added with ATRA (Sigma-Aldrich); 1
µmol/l ATRA was added each day for 5 days, in accordance
with the procedure described by Almand and coworkers [8].
Phenotype and functional analyses were conducted after 5
days with or without ATRA treatment.
Lymphocyte culture
Lymphocytes were cultured from MNCs in lymphocyte
medium: RPMI 1640 containing 10% AB serum, 1 mmol/l L-
glutamine, 2% pyruvate, 1% nonessential amino acids (Bio-
products, Gagny, France), 100 µg/ml streptomycin, 100 IU/ml
penicillin and 150 IU/ml IL-2 (Proleukin®; Chiron, Suresnes,
France). After 8 days in culture (density 106 cells/ml), lym-
phocytes were stimulated with DC-Tuper. Number, phenotypic
and functional characteristics of lymphocytes were evaluated
7 days after DC-Tuper stimulation. Viability was evaluated using
the trypan blue exclusion test. Controls were performed with
nonstimulated lymphocytes.
Flow cytometry analysis
Cells (105) were suspended in phosphate-buffered saline sup-
plemented with 0.5% bovine serum albumin and labelled for
characterization of lymphocyte or DC phenotype by incubation
at 4°C for 30 min with the following PE-, FITC-, or PC5-conju-
gated antibodies and corresponding isotypes: anti-CD3
(clone UCTH1), anti-CD4 (13B8.2), anti-CD8 (B9 11), anti-
CD25 (B1.49.9), anti-CD40 (mAb 89), anti-CD56 (NKH-1),
anti-αβ-TCR (BMA 031), anti-γδ-TCR (immu 510), anti-CD80
(MAB 104), anti-CD83 (HB15A) and anti-CD152 (CTLA-4;
after saponin permeabilization) from Immunotech (Marseille,
France); anti-CD11c (S-HCL-3), anti-HLA-DR (L243) andBreast Cancer Research    Vol 7 No 3    Gervais et al.
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Lin1 cocktail (anti-CD3, anti-CD14, anti-CD16, anti-CD19,
anti-CD20 and anti-CD56) from Becton Dickinson/Pharmin-
gen (CA, USA); and CD86 (BU63) from Immunotech (Oxford,
UK). Cells were washed and suspended in 250 µl phosphate-
buffered saline added with 0.3% formol. CD4+CD25+CTLA4+
was considered to be the T regulatory cell phenotype, in
accordance with the findings of Jonuleit and coworkers [19].
Data analysis was performed using a FACScan flow cytometer
(Becton Dickinson).
Cytotoxicity assays
T-cell mediated cytotoxicity was tested in triplicate with a
standard 51Cr release assay. The assays were conducted in U-
bottomed microtitre plates. Depending on the assays, target
cells were M74 tumour cell line or K562 cells pulsed with 51Cr
([51Cr]sodium chromate; Amersham Life Sciences, Bucking-
hamshire, England) for 1 hour.
A total of 5000 target cells/well were mixed with effector cells
(ratio of effector to target cells 50:1) and incubated for 4
hours. Chromium release was assessed in culture superna-
tants using a γ-counter (Topcount, Packard Instrument,
Rungis, France). Specific release was calculated as follows:
([mean experimental counts/min - mean spontaneous counts/
min]/ [mean maximum counts/min - mean spontaneous
counts/min]) × 100.
IFN-γ production
Responder cells were evaluated for their production of IFN-γ in
response to contact with antigenic cells. Analyses were per-
formed 8 days after stimulation with DC-Tuper. Briefly 2 × 105
M74 cells were seeded in 24-well plates for 12 hours. The
supernatant was discarded before adding 105 lymphocytes in
a final volume of 500 µl of medium without IL-2. The plates
were then incubated at 37°C for 72 hours and IFN-γ was
measured in supernatant using enzyme-linked immunosorbent
assay methods, in accordance with the manufacturer's instruc-
tions (Ready-set-Go®; eBioscience). Duplicate wells were run
for each assay.
Statistical analysis
Each assay was repeated with at least three different donors
or patients. The nonparametric Mann–Whitney rank test was
used for statistical analysis.
Results
Yield and characteristics of dendritic cells
After 7 days in culture with GM-CSF and IL-4, a mean of
12.5% of the blood MNCs from healthy donors differentiated
into immature DCs (Table 1). These cells were predominantly
HLA-DR+CD11c+ (94 ± 4%) and CD11c+Lin- (87 ± 13 %),
which is characteristic of myeloid DCs. The yield of immature
DCs was reduced after the same procedure was conducted in
MNCs from patients with cancer (Table 1), and this reduction
was significant for MNCs from patients with breast cancer.
These patients had normal blood monocyte counts (0.44 ±
0.09 Giga/l). Furthermore, immature DCs prepared from
peripheral blood MNCs from breast cancer patients
expressed high levels of CD11c (79 ± 14% CD11c+Lin-), but
large individual differences in HLA-DR expression were
recorded. The percentages of HLA-DR+Lin- cells were signifi-
cantly reduced and HLA-DR-Lin-  significantly increased in
patients with breast cancer (Fig. 1).
This latter observation led us to focus our DC investigations on
breast cancer patients. On comparing the expressions of
CD40, CD83 and CD86 on immature DCs between healthy
donors (n = 6) and patients with breast cancer (n = 10), no
significant differences were observed (CD40: 87 ± 7% versus
78.5 ± 16%, respectively; CD83: 6 ± 6% versus 10 ± 10%;
and CD86: 82 ± 14% versus 69 ± 22%). For patients with
colorectal cancer or renal cell carcinoma, percentages of
HLA-DR-Lin- cells in DCs were not significantly enhanced
when compared with those for healthy donors (Fig. 1).
The phagocytic capacity of immature DCs from breast cancer
patients was similar to that of immature DCs from healthy
donors (respectively; at 37°C: 42 ± 9% and 44 ± 15%; and
at 4°C: 5 ± 1% and 2 ± 1%). Mean fluorescence intensity after
2 hours of co-culture with FITC-labelled bacteria was 653 ±
56 and 656 ± 30 for patients and healthy donors, respectively.
Table 1
Dendritic cell yield in patients with cancer and healthy donors
DC source DC yield (%)
Healthy donors (n = 8) 12.5 ± 5.0
Patients with colorectal cancer (n = 4) 5.9 ± 2.6
Patients with breast cancer (n = 6) 3.1 ± 1.2*
Peripheric blood mononuclear cells (PBMCs) were cultured with granulocyte–macrophage colony-stimulating factor and IL-4. Data presented are 
the dendritic cell (DC) yield after 7 days: number of CD11c+Lin- cells/number of PBMCs at day 0. DCs were prepared from blood of healthy 
donors, patients with colorectal cancer, or patients with breast cancer. *P < 0.01 versus donors.Available online http://breast-cancer-research.com/content/7/3/R326
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Maturation of dendritic cells
For donors and patients, the three maturation cocktails
induced significant increases in expression of CD80 and
CD83 markers (Table 2, Fig. 2). However, the level of matura-
tion reached by DCs was weaker for patients than for donors;
whatever the combination of maturating agents used, we
observed lesser expression of mature DC markers in patients
(Fig. 2). For donors, high percentages of CD86- and CD40-
expressing cells were similarly observed in immature and
mature DCs (Table 2). These markers were heterogeneously
expressed in patients. IL-10 and IL-12 production by immature
DCs was similar in cells from donors and patients (Table 2).
Interestingly, maturation induced by Ribomunyl®/Imukin® stim-
ulated IL-12 production more for DCs from patients than for
DCs from donors (Table 2).
Dendritic cell mediated T-cell stimulation
When lymphocytes were subjected to DC-Tuper stimulation,
expansion was observed. The Expanding Index was not signif-
icantly greater in healthy donors (7.5 ± 2; n = 7) than in cancer
patients (5 ± 2.5; n = 5). However, contrary to our observa-
tions in healthy donors, the cytolytic activity of lymphocytes
against the M74 cell line was not significantly enhanced after
DC-Tuper stimulation for breast cancer patients (Fig. 3), which
indicates that DC-mediated T-cell stimulation was unsuccess-
ful in the patients.
In addition, the basic cytotoxic activity of lymphocytes against
the M74 cell line was significantly less for cancer patients than
for healthy donors (Fig. 3). The differences persisted after DC-
Tuper stimulation. In contrast, nonspecific lysis of the natural
killer (NK) cell sensitive K562 cell line remained unchanged
after DC-Tuper stimulation both for donors and for patients
(respectively: from 51 ± 38% to 51 ± 25% lysis and from 19
± 18% to 23 ± 23% lysis). Taken together, these observations
suggest that TA-specific T cells were induced in donors but
not in all of the breast cancer patients. No correlation could be
established between reduced cytotoxic activity of lym-
phocytes from patients (against M74 or NK-sensitive cell lines)
and percentage of regulatory T cells in the bulk (0.17 ± 0.14%
CD4+CD25+CTLA4+ cells; n = 11).
Lymphocyte phenotype and IFN-γ production
Basic IFN-γ production in response to contact with M74 cells
was similarly heterogeneous for lymphocytes from patients
and those from donors. After DC-Tuper  stimulation,
enhancement in IFN-γ production – a marker of T-helper-1
response – was consistently observed in lymphocytes from
Table 2
Cell surface phenotype of immature and mature dendritic cells from breast cancer patients
Donors/patients Immature DCs/mature DCs
Healthy donors
Donor M13 N14 015
CD40 79/95 80/97 84/96
CD80 0.1/90 1/97 18/91
CD83 2/52 8/48 19/40
CD86 85/98 68/98 57/97
IL-10 43/46 47/214 89/112
IL-12 5/400 7/29 5/182
Patients with breast cancer
P a t i e n t S 2 1 9S 2 2 1S 2 2 2
CD40 91/93 42/86 77/86
CD80 3/84 4/76 4.5/72
CD83 8/17 14/66 14/72
CD86 87/89 25/86 68/89
IL-10 46/0 57/132 30/63
IL-12 bdl/2154 bdl/1280 bdl/1261
Data are expressed as the percentage of HLA-DR+ cells expressing CD40, CD80, CD83 and CD86, and IL-10 and IL-12 production by dendritic 
cells (DCs) before and after maturation with cocktail C: Ribomunyl®/Imukin®. Data are individual values from patients S219, S221 and S222. 
Controls are from three different donors (M13, N14, O15). bdl, below the detection limit; DC, dendritic cell.Breast Cancer Research    Vol 7 No 3    Gervais et al.
R331
healthy donors (Table 3); this was in contrast to patients, for
whom enhancement was seen only in two out of six assays.
Considerable reduction in IFN-γ production was seen in lym-
phocytes from patient S137, indicating that autologous DCs
were not immunogenic in the assay (Table 3). Phenotypic
characterization revealed 71% HLA-DR-Lin- cells in DCs from
patient S137.
Lymphocytes from donors and cancer patients were of similar
phenotype after 15 days in culture with 150 UI IL-2 (Table 4).
Of the cells, 70% were T lymphocytes and more than 50%
were CD8+ T cells. Single stimulation with DC-Tuper did not
changed the respective percentages of CD4+ T cell, CD8+ T
cell, or γδ T cell subpopulations. In addition, the percentages
of regulatory T cells remained similar after DC-Tuper stimula-
tion, at 0–0.5% of cells.
Influence of putrescine treatment on dendritic cell 
phenotype
As shown in Fig. 1, of cells prepared from MNCs from donors
according to the classic procedure for preparing immature
DCs, a mean of only 4.6% had the HLA-DR-Lin- phenotype. An
18-hour treatment with 10 mmol/l putrescine increased this
percentage to 29.5% (Fig. 4). Expression of other surface
markers (CD40, CD80, CD83 and CD86) was not changed
by putrescine treatment (data not shown). Putrescine was
internalized by DCs because intracellular putrescine concen-
trations were dramatically enhanced after treatment (data not
shown).
Figure 1
Phenotype of cells collected after immature dendritic cell preparation  procedure in cancer patients Phenotype of cells collected after immature dendritic cell preparation 
procedure in cancer patients. Peripheral blood mononuclear cells from 
healthy donors (n = 11) or patients with colorectal cancer (n = 7), renal 
cell carcinoma (n = 10), or breast cancer (n = 15) were depleted of 
lymphocytes (2-hour adherence step) and cultured for 7 days in the 
presence of granulocyte–macrophage colony-stimulating factor and IL-
4. Data are expressed as the percentage of cells (with standard error) 
expressing the HLA-DR+Lin- and HLA-DR-Lin- phenotype. *P < 0.01 
versus healthy donors.
Figure 2
Maturation of dendritic cells (DCs) from healthy donors or from breast  cancer patients Maturation of dendritic cells (DCs) from healthy donors or from breast 
cancer patients. Data are expressed as the percentage of the cells 
(with standard error) expressing the CD80, CD83 and CD86 surface 
markers after treatment of immature DCs with a combination of maturat-
ing agents: (a) tumour necrosis factor (TNF)-α/lipopolysaccharide 
(LPS)/CD40L (n = 3); (b) IL-1β/IL-6/TNF-α/prostaglandin (PG)E2 (n = 
4–5); and (c) Ribomunyl®/Imukin® (n = 3). aDifferent from correspond-
ing donors in each individual assay.Available online http://breast-cancer-research.com/content/7/3/R326
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When DCs were treated daily for 5 days with 1 µmol/l ATRA,
the phenotypic change induced by putrescine was reversed
(Fig. 4).
Putrescine-treated dendritic cells are defective in their 
ability to stimulate T cells
When DCs from donors were treated with putrescine, their
ability to stimulate autologous T cells was significantly
reduced. Following the DC-Tuper stimulation procedure, the
Expanding Index of T cells declined by a mean 30 ± 11%
when DCs were treated with putrescine (3.3 ± 1.9 versus 4.6
± 2.5). In addition, specific cytolytic activity of DC-Tuper-stimu-
lated lymphocytes was decreased when DCs were treated
with putrescine (Fig. 5). This reduction was consistently
observed in all donors (n = 6). Treatment with ATRA reversed
this putrescine-induced deficiency in DCs and restored cyto-
lytic activity against M74 cells to normal values. A similar
increase was repeatedly observed for all donors. These
changes were not observed when the K562 target cells were
used for nonspecific NK-type cytolytic activity (data not
shown).
Discussion
In recent years several groups have described defective
immune function in tumour-bearing animals [18,20,21] and in
cancer patients [8,22,23]. Of note, it was reported that factors
produced by tumour cells could influence differentiation of
DCs from CD34+ progenitors, and that low concentrations of
IL-4 could reverse the inhibitory effect of cancer cell condi-
tioned medium, at least in terms of phenotype and some func-
tional differentiation of DCs [22]. We show here that, even in
the presence of IL-4, differences in differentiation of circulating
Table 3
Lymphocyte IFN-γ production after DC-Tuper stimulation
Donors/patients IFN-γ (pg/ml)
NSL NSL + DC-Tuper
Donors
C3 516 1581
G7 52 257
H8 17 133
B2 0 8
Breast cancer patients
S97 18 420
S101 12 908
S137 339 165
S108 418 176
S126 13 13
S94 13 10
IFN-γ production (pg/ml) was measured in response to tumour cells. Controls were nonstimulated lymphocytes (NSL). Data are individual values 
from four different donors and six breast cancer patients. DC-Tu, dendritic cells pulsed with treated tumour cells.
Figure 3
Cytolytic activity of lymphocytes from healthy donors or breast cancer  patients against the M74 cell line Cytolytic activity of lymphocytes from healthy donors or breast cancer 
patients against the M74 cell line. Lymphocytes are from donors (n = 5) 
or from cancer patients (n = 6), and were stimulated with autologous 
immature dendritic cells (DCs) pulsed with peroxide-treated M74 cells 
(DC-Tuper). Controls are nonstimulated lymphocytes (NSL). Values are 
expressed as cytolytic activity (with standard error) against M74 target 
cell line. *P < 0.03 versus NSL; †P < 0.05 versus corresponding 
donors.Breast Cancer Research    Vol 7 No 3    Gervais et al.
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monocytes into DCs persisted in cancer patients as compared
with healthy donors. Using the classic procedure of blood
monocyte derived DC culture (in the presence of IL-4 and GM-
CSF), the ex vivo yield of DCs was found to be significantly
reduced in patients with cancer, particularly in those with
breast cancer. Furthermore, the phenotype of collected cells
using this procedure was different in patients with breast can-
cer. Expression of MHC class II (HLA-DR+Lin- cells) was found
to be lower and the percentage of HLA-DR-Lin- to be higher
than in donors. In contrast, these subpopulations were not sig-
nificantly modified in patients with colon or renal cell
carcinoma.
Whatever combination of maturating agents was used, signif-
icantly lower expressions of mature DC markers were
observed in patients with breast cancer. Maturation induced
by Ribomunyl®/Imukin® resulted in lower expressions of CD80
and CD86 in patients than in donors, but, interestingly, it also
resulted in greater production of IL-12.
Other groups have reported that, in breast cancer patients,
monocyte-derived DCs have substantially lower level of
expression of HLA-DR than do DCs isolated from control
donors, leading to a reduced ability to stimulate allogenic and
Flu-specific T-cell responses [8]. We confirm here that DCs
from such patients not only exhibit low expression of MHC
class II but they also have reduced ability to cross-prime exog-
enous antigens. Stimulation of CTLs by pulsed DCs was less
efficient in patients than in donors. In a similar procedure for
lymphocyte stimulation, using the same antigen preparation
(peroxide-treated tumour cells) and tumour target (M74 cell
line), we repeatedly observed defective stimulation when DCs
were from patients with breast cancer. In general, the natural
cytolytic activity of lymphocytes against the M74 or NK target
cell line was found to be lower in patients than in donors.
Unlike donors, patients were not selected for their expression
of HLA-A2 class I molecules. This could represent an advan-
tage in terms of CTL activation, but the opposite was
observed. Cytolytic activity was enhanced by up to 40% when
DCs were from donors but only up to 10% when they were
from patients.
IFN-γ production after DC-Tu stimulation was repeatedly found
to be enhanced in donors. In contrast, nonspecific lysis of the
Table 4
Phenotype of DC-Tuper stimulated lymphocytes
Phenotype (%) Donor Breast cancer
NSL NSL + DC-Tuper NSL NSL + DC-Tuper
CD3+CD56- 73 ± 30 76 ± 24 75 ± 17 73 ± 15
CD3-CD56+ 6 + 8 5 ± 6 10 ± 13 5 ± 5
CD3+CD56+ 18 ± 21 18 ± 18 11 ± 5 20 ± 13
CD4+ T cell 28 ± 30 24 ± 27 29 ± 21 31 ± 22
CD8+ T cell 51 ± 21 57 ± 18 51 ± 19 59 ± 18
TCR α/β 75 ± 23 77 ± 23 70 ± 20 83 ± 12
TCR γ/δ 14 ± 15 13 ± 18 14 ± 11 11 ± 12
Cells are from healthy donors (n = 3) or breast cancer patients (n = 6). The percentage of positive cells for lymphocyte markers was measured in 
a 99% CD45+ population. Data are expressed as mean ± standard deviation. DC-Tu, dendritic cells pulsed with treated tumour cells; NSL, 
nonstimulated lymphocytes.
Figure 4
Effect of putrescine and all-trans retinoic acid (ATRA) on immature den- dritic cell (DC) phenotype Effect of putrescine and all-trans retinoic acid (ATRA) on immature den-
dritic cell (DC) phenotype. Cells were collected after immature DC 
preparation procedure (imm DC; n = 11) and treated with 10 mmol/l 
putrescine (Put; n = 10). To putrescine-treated DCs was added 1 
µmol/l ATRA (Put + ATRA; n = 5). Data are expressed as percentage 
of cells (with standard error) expressing the HLA-DR+Lin- and HLA-DR-
Lin- phenotypes. *P < 0.01 versus imm DCs; **P < 0.02 versus 
putrescine-treated imm DCs.Available online http://breast-cancer-research.com/content/7/3/R326
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NK-sensitive K562 cell line was the same after DC-Tuper stim-
ulation, clearly indicating that in donors DC-Tuper stimulation
induced TA-specific T cells. Induction of TA-specific T cells
did not occur in all cancer patients. Blockade of DCs at an
early stage in differentiation could be responsible for this
inconsistency between patients. For example, in patient S137
a high percentage of HLA-DR-Lin- cells was observed in DCs,
and concomitantly IFN-γ lymphocyte production was reduced
twofold after DC-Tu stimulation, indicating that DCs were not
only nonimmunogenic but were actually tolerogenic in this
patient. However, the percentage of regulatory T cells was not
changed after DC-Tu stimulation (<0.1% in S137). Correla-
tion could not be demonstrated in this study between clinical
grade of disease and HLA-DR-Lin- DC phenotype. Defective
function and poor ability of immature DCs to mature in some
patients could represent an additional reason why DC cell
therapy in cancer patients has, contrary to expectations, not
yet yielded significant clinical responses [2].
Defective DC function can be mimicked by adding putrescine
to the culture medium of DCs from healthy donors. The per-
centage of cells with HLA-DR-Lin- phenotype was found to be
enhanced after putrescine treatment. In addition, expansion
and final cytolytic activity of lymphocytes was reduced follow-
ing the DC-Tuper stimulation procedure, leading us to conclude
that adding putrescine to the microenvironment of antigen-
presenting cells blocks their ability to cross-prime exogenous
antigens efficiently, indicating a reduction in their immuno-
genic function. It was reported by other authors that spermine,
another polyamine, is responsible for severe inhibition in proin-
flammatoty cytokine synthesis when added to cultures of
human peripheral blood MNCs stimulated with lipopolysac-
charide [24].
Our group previously established that polyamine deprivation
leads to significant reduction in tumour growth in murine
experimental models. Consistent with that effect, an enhance-
ment in CD8+ T lymphocytes was observed in the spleens of
the animals [18]. With similar experimental tumours we
observed that combining polyamine deprivation with
cyclophosphamide, which is known to downregulate regula-
tory T cells [25], enhances macrophage tumouricidal activity,
indicating that the two treatments have synergistic effects
[26].
In addition, breast cancer tissues are characterized by high
polyamine levels. In a study including 174 patients with inva-
sive breast cancer [27], a correlation was established
between enhancement of putrescine and spermidine levels
and tumour aggressiveness. Taken together, these observa-
tions led to the conclusion that putrescine release by tumour
cells may be involved in the defective DC function observed in
breast cancer patients. Interestingly, we showed in the present
study that in vitro treatment of DCs with ATRA could reverse
the putrescine-induced deficiency in DC function. ATRA and
retinoic derivatives are known to influence DC differentiation,
favouring a T-helper-1 response [28]. Further investigations
are needed to detail the mechanism underlying the reversal in
putrescine-induced deficiency in DC function. Nevertheless,
use of ATRA treatment to initiate TA-specific CTL expansion in
cancer patients could be of particular interest.
Conclusion
Taken together, our findings are in agreement with those from
Gabrilovitch and coworkers [7] on the contribution of imma-
ture myeloid DCs to cancer-induced immunosuppression – a
mechanism that is involved in the escape of tumours from
immune system control. Breast cancers are known frequently
to over-express several TAs, such as carcinoembryonic anti-
gen, MUC1, HER2/neu, P53 and members of the MAGE fam-
ily, but little is known about detection of pre-existing T-cell
responses, and the rationale for initiating vaccination strate-
gies remains to be fully established. Nevertheless, a phase I
clinical trial using vaccine prepared by fusing autologous
tumor and DCs (32 patients included) [29] found that two
patients with metastatic breast cancer exhibited disease
regression. Our opinion is that future vaccination strategies
could be improved in view of the present data. Procedures
(established with cells from donors) must be adapted to the
characteristics of the patient's DCs. One simple treatment
would be use ATRA to reverse blockade of DC function. The
Ribomunyl®/Imukin® combination has demonstrated ability to
induce DC maturation.
Figure 5
Cytolytic activity of lymphocytes stimulated with putrescine and all-trans  retinoic acid (ATRA) treated dendritic cells (DCs) Cytolytic activity of lymphocytes stimulated with putrescine and all-trans 
retinoic acid (ATRA) treated dendritic cells (DCs). Immature DCs were 
from healthy donors and were treated with putrescine (Put) with or with-
out ATRA before DCs pulsed with treated tumour cells (DC-Tuper) prep-
aration. Autologous lymphocytes were stimulated with DC-Tuper, and 
data are expressed as cytolytic activity (with standard error) against 
M74 target cell line. Presented data are from seven different donors. 
Controls are nonstimulated lymphocytes (NSL). Decrease in M74 lysis 
was repeatedly observed for each of the donors in DC + Put compared 
with DC, and increased in DC + Put + ATRA as compared with DC + 
Put. *P < 0.05 versus NSL.Breast Cancer Research    Vol 7 No 3    Gervais et al.
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